Assessment of reliability of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer

Assessment of reliability of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer - PD-L1 expression in NSCLC with small biopsy samples

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027030

Enrollment

100

Registered

2017-04-18

Start date

2017-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed advanced non-small cell lung cancer (NSCLC) 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 3) Patient with evaluable lesion based on RECIST 4) Written informed consent

Exclusion criteria

Exclusion criteria: Other cases attending physician it is determined unsuitable for registration of the study

Design outcomes

Primary

Measure	Time frame
PD-L1 expression status of small samples with each procedure (under rigid bronchoscopy, flexible bronchoscopy, CT & US-guided core-needle, excisional method)	—

Secondary

Measure	Time frame
1) Total number of tumor cells 2) Comparison of sample size, nunber of tumor cells and PD-L1 expression in BF 1T260 and BF P260F 3) Concordance rate of PD-L1 expression status in biopsy and surgical materials. 4) Efficacy for administration of PD-1 immune checkpoint inhibitor antibody	—

Countries

Japan

Contacts

Public ContactKEI MORIKAWA

St. Marianna University School of Medicine Division of Respiratory Diseases, Department of Internal Medicine

mokke5454@yahoo.co.jp044-977-8111

Outcome results